Market Overview:
The global clinical biomarker testing market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicine, and technological advancements in biomarker testing. Based on type, the global clinical biomarker testing market is segmented into cancer, metabolism, infectious disease, cardiology, neurology and immunological disease. The cancer segment is expected to account for the largest share of the global clinical biomarker testing market in 2018. This can be attributed to increasing incidence of cancer and growing demand for early diagnosis and treatment of cancer patients. Based on application, the global clinical biomarker testing market is segmented into drug discovery & development; nutrigenomics; toxicologytesting; personalized medicine; functional genomics & proteomics research laboratories).
Product Definition:
Clinical biomarker testing is the process of detecting and measuring biomarkers in blood, tissue, or other bodily fluids to help diagnose and monitor diseases. Biomarkers are proteins, genes, or other molecules that indicate the presence or progress of a disease. Clinical biomarker testing can help doctors identify early signs of disease, determine the best treatment for a patient, and track the effects of treatment.
Cancer:
The global cancer, it's usage and growth factor in clinical biomarker testing market size was valued at USD 1.8 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of oncology diseases coupled with rising geriatric population base is estimated to drive the market growth during the forecast period.
Metabolism:
Metabolism is the sum total of all chemical reactions that take place in a living organism to sustain life. It is used as an important clinical biomarker for determining disease progression and monitoring drug response in patients. The most common ways to measure metabolism include urinary excretion, blood tests, and breath tests.
Application Insights:
The drug discovery segment dominated the global market in 2017 and is expected to witness significant growth over the forecast period. This can be attributed to an increase in R&D activities pertaining to new drug development for various diseases. A rise in government funding for research related to disease mechanisms, diagnosis, treatment options and biomarkers is also a key factor driving this segment.
Nutrigenomics plays a major role in personalized medicine through pharmacogenomics and pharmacogenetics which involves analysis of genetic information from patients regarding drugs & medicines they are taking or have taken before. Personalized medicine based on genomic data helps determine appropriate therapy with minimal side effects while improving patient compliance with medication regimen leading to improved health outcomes.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, continuous research activities for development of novel tests, and high adoption rate for advanced diagnostic techniques. Moreover, increasing prevalence of chronic diseases is also expected to boost regional growth during the forecast period. For instance, according to CDC estimates around 30 million people in U.S have diabetes and this number is growing rapidly due to obesity & Inactivity (obesity), tobacco smoking (tobacco smoking) & Alcohol consumption (alcohol consumption).
Asia Pacific region accounted for over 18% share owing to rising healthcare expenditure by governments as well as private sectors coupled with increasing awareness regarding early diagnosis among patients pertaining various diseases such as cancer.
Growth Factors:
- Increasing incidence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases such as cancer, cardiovascular disease, diabetes, and respiratory disorders are responsible for over 60% of all deaths worldwide. This is expected to drive the demand for clinical biomarker testing services in the coming years.
- Technological advancements: The field of biomarker research is constantly evolving with new technological advancements being made every day. This has led to increased accuracy and efficiency in clinical biomarker testing procedures. As a result, more healthcare providers are adopting these tests for diagnosis and treatment purposes.
Scope Of The Report
Report Attributes
Report Details
Report Title
Clinical Biomarker Testing Market Research Report
By Type
Cancer, Metabolism, Infectious Disease, Cardiology, Neurology, Immunological Disease
By Application
Drug Discovery, Nutrigenomics, Toxicology Testing, Personalized Medicine, Functional Genomics
By Companies
Abbott Laboratories, AbbVie Inc., Adaptive Biotechnologies, Agilent Technologies, BD, Becton Dickinson, Bio-Rad Laboratories, Danaher Corporation, Merck and Co., Thermofisher Scientific
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
175
Number of Tables & Figures
123
Customization Available
Yes, the report can be customized as per your need.
Global Clinical Biomarker Testing Market Report Segments:
The global Clinical Biomarker Testing market is segmented on the basis of:
Types
Cancer, Metabolism, Infectious Disease, Cardiology, Neurology, Immunological Disease
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Drug Discovery, Nutrigenomics, Toxicology Testing, Personalized Medicine, Functional Genomics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- AbbVie Inc.
- Adaptive Biotechnologies
- Agilent Technologies
- BD
- Becton Dickinson
- Bio-Rad Laboratories
- Danaher Corporation
- Merck and Co.
- Thermofisher Scientific
Highlights of The Clinical Biomarker Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cancer
- Metabolism
- Infectious Disease
- Cardiology
- Neurology
- Immunological Disease
- By Application:
- Drug Discovery
- Nutrigenomics
- Toxicology Testing
- Personalized Medicine
- Functional Genomics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Clinical Biomarker Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Clinical biomarker testing is a type of diagnostic testing that uses biomarkers to identify specific diseases or conditions. These tests can be used to help doctors diagnose and monitor patientsu2019 health.
Some of the major companies in the clinical biomarker testing market are Abbott Laboratories, AbbVie Inc., Adaptive Biotechnologies, Agilent Technologies, BD, Becton Dickinson, Bio-Rad Laboratories, Danaher Corporation, Merck and Co., Thermofisher Scientific.
The clinical biomarker testing market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Clinical Biomarker Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Clinical Biomarker Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Clinical Biomarker Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Clinical Biomarker Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Clinical Biomarker Testing Market Size & Forecast, 2018-2028
4.5.1 Clinical Biomarker Testing Market Size and Y-o-Y Growth
4.5.2 Clinical Biomarker Testing Market Absolute $ Opportunity
Chapter 5 Global Clinical Biomarker Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Clinical Biomarker Testing Market Size Forecast by Type
5.2.1 Cancer
5.2.2 Metabolism
5.2.3 Infectious Disease
5.2.4 Cardiology
5.2.5 Neurology
5.2.6 Immunological Disease
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Clinical Biomarker Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Clinical Biomarker Testing Market Size Forecast by Applications
6.2.1 Drug Discovery
6.2.2 Nutrigenomics
6.2.3 Toxicology Testing
6.2.4 Personalized Medicine
6.2.5 Functional Genomics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Clinical Biomarker Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Clinical Biomarker Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Clinical Biomarker Testing Analysis and Forecast
9.1 Introduction
9.2 North America Clinical Biomarker Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Clinical Biomarker Testing Market Size Forecast by Type
9.6.1 Cancer
9.6.2 Metabolism
9.6.3 Infectious Disease
9.6.4 Cardiology
9.6.5 Neurology
9.6.6 Immunological Disease
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Clinical Biomarker Testing Market Size Forecast by Applications
9.10.1 Drug Discovery
9.10.2 Nutrigenomics
9.10.3 Toxicology Testing
9.10.4 Personalized Medicine
9.10.5 Functional Genomics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Clinical Biomarker Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Clinical Biomarker Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Clinical Biomarker Testing Market Size Forecast by Type
10.6.1 Cancer
10.6.2 Metabolism
10.6.3 Infectious Disease
10.6.4 Cardiology
10.6.5 Neurology
10.6.6 Immunological Disease
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Clinical Biomarker Testing Market Size Forecast by Applications
10.10.1 Drug Discovery
10.10.2 Nutrigenomics
10.10.3 Toxicology Testing
10.10.4 Personalized Medicine
10.10.5 Functional Genomics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Clinical Biomarker Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Clinical Biomarker Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Clinical Biomarker Testing Market Size Forecast by Type
11.6.1 Cancer
11.6.2 Metabolism
11.6.3 Infectious Disease
11.6.4 Cardiology
11.6.5 Neurology
11.6.6 Immunological Disease
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Clinical Biomarker Testing Market Size Forecast by Applications
11.10.1 Drug Discovery
11.10.2 Nutrigenomics
11.10.3 Toxicology Testing
11.10.4 Personalized Medicine
11.10.5 Functional Genomics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Clinical Biomarker Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Clinical Biomarker Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Clinical Biomarker Testing Market Size Forecast by Type
12.6.1 Cancer
12.6.2 Metabolism
12.6.3 Infectious Disease
12.6.4 Cardiology
12.6.5 Neurology
12.6.6 Immunological Disease
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Clinical Biomarker Testing Market Size Forecast by Applications
12.10.1 Drug Discovery
12.10.2 Nutrigenomics
12.10.3 Toxicology Testing
12.10.4 Personalized Medicine
12.10.5 Functional Genomics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Clinical Biomarker Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Clinical Biomarker Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Clinical Biomarker Testing Market Size Forecast by Type
13.6.1 Cancer
13.6.2 Metabolism
13.6.3 Infectious Disease
13.6.4 Cardiology
13.6.5 Neurology
13.6.6 Immunological Disease
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Clinical Biomarker Testing Market Size Forecast by Applications
13.10.1 Drug Discovery
13.10.2 Nutrigenomics
13.10.3 Toxicology Testing
13.10.4 Personalized Medicine
13.10.5 Functional Genomics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Clinical Biomarker Testing Market: Competitive Dashboard
14.2 Global Clinical Biomarker Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 AbbVie Inc.
14.3.3 Adaptive Biotechnologies
14.3.4 Agilent Technologies
14.3.5 BD
14.3.6 Becton Dickinson
14.3.7 Bio-Rad Laboratories
14.3.8 Danaher Corporation
14.3.9 Merck and Co.
14.3.10 Thermofisher Scientific
